JP4896005B2 - Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法 - Google Patents

Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法 Download PDF

Info

Publication number
JP4896005B2
JP4896005B2 JP2007506363A JP2007506363A JP4896005B2 JP 4896005 B2 JP4896005 B2 JP 4896005B2 JP 2007506363 A JP2007506363 A JP 2007506363A JP 2007506363 A JP2007506363 A JP 2007506363A JP 4896005 B2 JP4896005 B2 JP 4896005B2
Authority
JP
Japan
Prior art keywords
peg
cells
polypeptide
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007506363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007531741A (ja
JP2007531741A5 (https=
Inventor
ケビン エム． クラチャー
ウェイン アール． キンズボゲル
パラブール ブイ． シバクマール
キャサリン イー． ヘンダーソン
Original Assignee
ザイモジェネティクス リミテッド ライアビリティ カンパニー
ブリストル−マイヤーズ スクウィブ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイモジェネティクス リミテッド ライアビリティ カンパニー, ブリストル−マイヤーズ スクウィブ カンパニー filed Critical ザイモジェネティクス リミテッド ライアビリティ カンパニー
Publication of JP2007531741A publication Critical patent/JP2007531741A/ja
Publication of JP2007531741A5 publication Critical patent/JP2007531741A5/ja
Application granted granted Critical
Publication of JP4896005B2 publication Critical patent/JP4896005B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007506363A 2004-04-02 2005-04-04 Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法 Expired - Lifetime JP4896005B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US55908104P 2004-04-02 2004-04-02
US60/559,081 2004-04-02
US60923804P 2004-09-13 2004-09-13
US60/609,238 2004-09-13
US63414404P 2004-12-08 2004-12-08
US60/634,144 2004-12-08
PCT/US2005/011450 WO2005097165A2 (en) 2004-04-02 2005-04-04 Il-28 and il-29 cysteine mutants for treating viral infection

Publications (3)

Publication Number Publication Date
JP2007531741A JP2007531741A (ja) 2007-11-08
JP2007531741A5 JP2007531741A5 (https=) 2008-03-06
JP4896005B2 true JP4896005B2 (ja) 2012-03-14

Family

ID=34965116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506363A Expired - Lifetime JP4896005B2 (ja) 2004-04-02 2005-04-04 Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法

Country Status (7)

Country Link
US (7) US20050244423A1 (https=)
EP (1) EP1750749A2 (https=)
JP (1) JP4896005B2 (https=)
AU (1) AU2005231476B2 (https=)
CA (1) CA2558829C (https=)
IL (1) IL177640A0 (https=)
WO (1) WO2005097165A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927040B2 (en) * 2000-06-30 2005-08-09 Zymogenetics, Inc. Interferon-like protein Zcyto21
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
EP1575609A4 (en) * 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
EP1927600A1 (en) 2003-08-07 2008-06-04 Zymogenetics, Inc. Homogeneous preparations of IL-28 and IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
WO2005097165A2 (en) 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
JP2009502803A (ja) * 2005-07-20 2009-01-29 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法
CA2616004A1 (en) * 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
WO2009009115A2 (en) * 2007-07-11 2009-01-15 Nevsky Pharmaceutical Development Liposome compositions for treatment of hepatitis c
US10071154B2 (en) * 2008-04-04 2018-09-11 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
JP2011522834A (ja) * 2008-06-05 2011-08-04 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用
WO2010045261A1 (en) * 2008-10-13 2010-04-22 Zymogenetics, Llc Single chain fc type iii interferons and methods of using same
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
CN102559737A (zh) * 2011-12-13 2012-07-11 江南大学 一种人白细胞介素29的变异体及其制备方法
AU2013323472B2 (en) * 2012-09-28 2018-07-05 Ellis KLINE Glycosidase regimen for treatment of infectious disease
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
CN114901822A (zh) 2019-12-23 2022-08-12 维萨梅布有限公司 用于同时调节基因表达的组合物和方法
US20230201308A1 (en) * 2020-02-06 2023-06-29 Eiger Biopharmaceuticals, Inc. Treatment of coronavirus infection with interferon lambda
WO2021159027A1 (en) * 2020-02-06 2021-08-12 Eiger Biopharmaceuticals, Inc. Treatment of coronavirus infection with interferon lambda
CN117024530B (zh) * 2023-07-20 2024-03-19 中国人民解放军空军军医大学 抗微生物肽Perceptide-TJ-2及其在制备广谱抗病毒药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055473A1 (en) * 2000-04-20 2002-05-09 Ganguly Ashit K. Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2002086087A2 (en) * 2001-04-20 2002-10-31 Zymogenetics, Inc. Cytokine protein family
JP2007528719A (ja) * 2003-08-07 2007-10-18 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９の均一な調製物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54096B1 (en) 1980-01-08 1989-06-21 Biogen Nv Dn sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6927040B2 (en) 2000-06-30 2005-08-09 Zymogenetics, Inc. Interferon-like protein Zcyto21
JP2004509617A (ja) 2000-09-08 2004-04-02 シェーリング　コーポレイション 哺乳動物遺伝子；関連試薬および方法
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
WO2002092762A2 (en) 2001-05-10 2002-11-21 Immunex Corporation Cytokine polypeptides
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
EP2295455A1 (en) 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Cytokine receptor
EP1575609A4 (en) * 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
WO2005097165A2 (en) * 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
JP2009502803A (ja) 2005-07-20 2009-01-29 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法
JP2011522834A (ja) 2008-06-05 2011-08-04 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055473A1 (en) * 2000-04-20 2002-05-09 Ganguly Ashit K. Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2002086087A2 (en) * 2001-04-20 2002-10-31 Zymogenetics, Inc. Cytokine protein family
JP2007528719A (ja) * 2003-08-07 2007-10-18 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９の均一な調製物

Also Published As

Publication number Publication date
EP1750749A2 (en) 2007-02-14
US20130022571A1 (en) 2013-01-24
US20110008280A1 (en) 2011-01-13
IL177640A0 (en) 2006-12-31
AU2005231476B2 (en) 2011-09-01
WO2005097165A2 (en) 2005-10-20
JP2007531741A (ja) 2007-11-08
US20050244423A1 (en) 2005-11-03
WO2005097165A3 (en) 2005-12-01
US8816053B2 (en) 2014-08-26
US20090018080A1 (en) 2009-01-15
US8283448B2 (en) 2012-10-09
AU2005231476A1 (en) 2005-10-20
CA2558829C (en) 2014-03-11
US20090263352A1 (en) 2009-10-22
US20110300101A1 (en) 2011-12-08
US20080075693A1 (en) 2008-03-27
CA2558829A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
JP4896005B2 (ja) Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
US20110182852A1 (en) Il28 and il29 truncated cysteine mutants and antiviral methods of using same
US8318147B2 (en) Use of IL-29 for treating a dengue virus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080117

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111219

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111220

R150 Certificate of patent or registration of utility model

Ref document number: 4896005

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term